title: [Role of 6% hydroxyethylstarch 130/0.4 and furosemide in the treatment of acute pancreatitis].
abstract: This study was conducted to observe the effects of intravenously administered 6% hydroxyethylstarch 130/ 0.4 solution and furosemide on the outcome of acute pancreatitis patients. Patients admitted to our center from October 16, 2007 through August 31, 2009 were given intravenous infusions of 6% hydroxyethylstarch 130/0. 4 solution (1 000-2 000 ml administered for an adult) soon after admission. At the same time, furosemide was administered as intravenous bolus, trying to maintain a fluid balance. The dose level of hydroxyethylstarch was gradually lowered from the second day after admission. A total of 135 patients (54% of patients with a Ranson's score > or = 3 and 61% with a Balthazar CT score > or = D) were treated with our protocol. Only 4% and 7% patients developed pancreatic and systemic complications respectively; only 1 patient underwent necrosectomy. The in-hospital mortality rate was 4%. It was estimated that, on the average, 18. 3% of blood volume was lost on admission. Our study suggest that intravenously administered 6% hydroxyethylstarch 130/0. 4 solution and furosemide might be beneficial for patients with acute pancreatitis. Plasma extravasation is a central event of acute pancreatitis. The reversal of hypovolemia is crucial for the success in treatment of acute pancreatitis.
authors.affiliation: Emergency Medical Center, Sichuan Provincial People's Hospital, Chengdu 610072, China.
authors.forename: Jiandong
authors.initials: J
authors.lastname: Wang
authors.forename: Youdai
authors.initials: Y
authors.lastname: Chen
authors.forename: Yun
authors.initials: Y
authors.lastname: Dong
authors.forename: Weijian
authors.initials: W
authors.lastname: Hu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Chang
authors.forename: Shiyan
authors.initials: S
authors.lastname: Feng
authors.forename: Jian
authors.initials: J
authors.lastname: Lin
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D020896:Hypovolemia / Q000517:prevention & control*; D007223:Infant; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D005665:Furosemide